MW Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug Elevidys, which is used to treat Duchenne muscular dystrophy.
While liver failure is a known possible side effect of Elevidys, it had not yet been reported until now, Sarepta (SRPT) said.
"Acute liver failure leading to death represents a severity of acute liver injury notpreviously reported for Elevidys, which to date has been used to treat more than 800 patients inclinical trials or as a prescribed therapy," the company said.
Prior to Tuesday's moves, Sarepta's stock was down 16.7% so far in 2025, while Nasdaq COMP has dropped 7.8%.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 18, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。